Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...
1d
Verywell Health on MSNA New FDA-Approved Antibiotic May Help Women With Recurring UTIsIf you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...
6d
Everyday Health on MSNFDA Approves the First New UTI Antibiotic in Nearly 30 YearsThis antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...
A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...
March 26, 2025 — The FDA has approved a new medication to treat uncomplicated urinary tract infections in women and girls aged 12 or older. It is the first in a new class of oral antibiotics ...
7d
Interesting Engineering on MSNNew hope for UTI patients as FDA approves first-of-its-kind antibiotic in 30 yearsThe U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...
The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...
Gepotidacin is an oral ... and vulvovaginal candidiasis. “The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results